155 related articles for article (PubMed ID: 14613454)
1. The economic impact of acute exacerbations of chronic bronchitis in the United States and Canada: a literature review.
Halpern MT; Higashi MK; Bakst AW; Schmier JK
J Manag Care Pharm; 2003; 9(4):353-9. PubMed ID: 14613454
[TBL] [Abstract][Full Text] [Related]
2. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group.
Grossman R; Mukherjee J; Vaughan D; Eastwood C; Cook R; LaForge J; Lampron N
Chest; 1998 Jan; 113(1):131-41. PubMed ID: 9440580
[TBL] [Abstract][Full Text] [Related]
3. Selection of clinical, patient-reported, and economic end points in acute exacerbation of chronic bronchitis.
Perfetto EM; Mullins CD; Subedi P; Li-McLeod J
Clin Ther; 2001 Oct; 23(10):1747-72. PubMed ID: 11726009
[TBL] [Abstract][Full Text] [Related]
4. The workplace impact of acute exacerbations of chronic bronchitis (AECB); A literature review.
Halpern MT; Polzin J; Higashi MK; Bakst A
COPD; 2004; 1(2):249-54. PubMed ID: 17136991
[TBL] [Abstract][Full Text] [Related]
5. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales.
McGuire A; Irwin DE; Fenn P; Gray A; Anderson P; Lovering A; MacGowan A
Value Health; 2001; 4(5):370-5. PubMed ID: 11705127
[TBL] [Abstract][Full Text] [Related]
6. Equal effectiveness of older traditional antibiotics and newer broad-spectrum antibiotics in treating patients with acute exacerbations of chronic bronchitis.
Peng CC; Aspinall SL; Good CB; Atwood CW; Chang CC
South Med J; 2003 Oct; 96(10):986-91. PubMed ID: 14570342
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year.
Torrance G; Walker V; Grossman R; Mukherjee J; Vaughan D; La Forge J; Lampron N
Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):499-520. PubMed ID: 10662396
[TBL] [Abstract][Full Text] [Related]
8. Optimizing economic outcomes in acute exacerbations of chronic bronchitis.
Destache CJ
Pharmacotherapy; 2002 Jan; 22(1 Pt 2):12S-17S; discussion 30S-32S. PubMed ID: 11791624
[TBL] [Abstract][Full Text] [Related]
9. Acute exacerbation of chronic bronchitis: disease-specific issues that influence the cost-effectiveness of antimicrobial therapy.
Saint S; Flaherty KR; Abrahamse P; Martinez FJ; Fendrick AM
Clin Ther; 2001 Mar; 23(3):499-512. PubMed ID: 11318083
[TBL] [Abstract][Full Text] [Related]
10. Costs of treating lower respiratory tract infections.
Monte SV; Paolini NM; Slazak EM; Schentag JJ; Paladino JA
Am J Manag Care; 2008 Apr; 14(4):190-6. PubMed ID: 18402511
[TBL] [Abstract][Full Text] [Related]
11. Antibiotics in the treatment of acute exacerbations of chronic bronchitis.
Dever LL; Shashikumar K; Johanson WG
Expert Opin Investig Drugs; 2002 Jul; 11(7):911-25. PubMed ID: 12084002
[TBL] [Abstract][Full Text] [Related]
12. Cost and clinical consequence of antibiotic non-adherence in acute exacerbations of chronic bronchitis.
Sorensen SV; Baker T; Fleurence R; Dixon J; Roberts C; Haider S; Hughes D
Int J Tuberc Lung Dis; 2009 Aug; 13(8):945-54. PubMed ID: 19723373
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and cost-effectiveness of antibiotic treatments for community acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB).
Lavoie F; Blais L; Castilloux AM; Scalera A; LeLorier J
Can J Clin Pharmacol; 2005; 12(2):e212-7. PubMed ID: 15998960
[TBL] [Abstract][Full Text] [Related]
14. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis.
Destache CJ; Dewan N; O'Donohue WJ; Campbell JC; Angelillo VA
J Antimicrob Chemother; 1999 Mar; 43 Suppl A():107-13. PubMed ID: 10225580
[TBL] [Abstract][Full Text] [Related]
15. Treatment cost of acute exacerbations of chronic bronchitis.
Niederman MS; McCombs JS; Unger AN; Kumar A; Popovian R
Clin Ther; 1999 Mar; 21(3):576-91. PubMed ID: 10321424
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care.
Llor C; Naberan K; Cots JM; Molina J; Miravitlles M
Int J Clin Pract; 2004 Oct; 58(10):937-44. PubMed ID: 15587773
[TBL] [Abstract][Full Text] [Related]
17. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis.
Wilson R; Jones P; Schaberg T; Arvis P; Duprat-Lomon I; Sagnier PP;
Thorax; 2006 Apr; 61(4):337-42. PubMed ID: 16449273
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB).
Grassi C; Casali L; Curti E; Tellarini M; Lazzaro C; Schito G;
J Chemother; 2002 Dec; 14(6):597-608. PubMed ID: 12583552
[TBL] [Abstract][Full Text] [Related]
19. Appropriateness of antibiotic prescribing in veterans with community-acquired pneumonia, sinusitis, or acute exacerbations of chronic bronchitis: a cross-sectional study.
Tobia CC; Aspinall SL; Good CB; Fine MJ; Hanlon JT
Clin Ther; 2008 Jun; 30(6):1135-44. PubMed ID: 18640469
[TBL] [Abstract][Full Text] [Related]
20. Treating acute exacerbations of chronic bronchitis and community-acquired pneumonia: how effective are respiratory fluoroquinolones?
Balter M; Weiss K
Can Fam Physician; 2006 Oct; 52(10):1236-42. PubMed ID: 17279183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
